<div id="readability-page-1"><p><span>Gilead Sciences (NASDAQ:GILD - Get Free Report)</span> had its price objective dropped by stock analysts at Daiwa Securities Group  from $161.00 to $150.00 in a report released on Tuesday,MarketScreener reports. The firm presently has an &#34;outperform&#34; rating on the biopharmaceutical company's stock. Daiwa Securities Group's target price indicates a potential upside of 14.66% from the stock's current price.</p><div><p><span></span><span>Get <strong>Gilead Sciences</strong> alerts:</span></p></div><ul><li>3 Blue-Chip Stocks Built for a Rotating Market</li></ul><p>Several other research firms also recently commented on GILD. Barclays began coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an &#34;equal weight&#34; rating and a $155.00 price objective for the company. Wells Fargo &amp; Company increased their price objective on Gilead Sciences from $150.00 to $165.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, February 11th. TD Cowen raised their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, February 11th. Cantor Fitzgerald decreased their price target on Gilead Sciences from $155.00 to $115.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, April 10th. Finally, Mizuho raised their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, February 18th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued  a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $156.62.</p><p><b>Check Out Our Latest Stock Report on GILD</b></p><h2>Gilead Sciences Stock Performance</h2><ul><li>These 3 Cash Flow Machines Provide Stability in Uncertain Markets</li></ul><p>GILD traded up $1.15 during trading on Tuesday, hitting $130.82. 392,453 shares of the company traded hands, compared to its average volume of 6,687,137. The firm has a market cap of $162.42 billion, a P/E ratio of 17.85 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences has a one year low of $104.46 and a one year high of $157.29. The stock's fifty day moving average is $137.46 and its 200 day moving average is $133.40. </p><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company's revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS.  As a group, equities analysts predict that  Gilead Sciences will post -0.78 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><ul><li>3 Cash-Flow Machines Investors May Want Heading Into 2026</li></ul><p>In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares of the company's stock, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company's stock, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock valued at $8,523,570 over the last quarter. 0.30% of the stock is owned by corporate insiders. </p><h2>Institutional Investors Weigh In On Gilead Sciences</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Vanguard Group Inc. grew its holdings in shares of  Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter.  State Street Corp boosted its position in  Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock valued at $7,393,921,000 after buying an additional 1,151,213 shares during the period.  Price T Rowe Associates Inc. MD grew its holdings in  Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the last quarter.  Bank of America Corp DE increased its position in shares of  Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares during the period.  Finally, Norges Bank bought a new position in shares of  Gilead Sciences during the fourth quarter valued at about $2,617,152,000. Institutional investors own  83.67% of the company's stock. </p><h2>About Gilead Sciences</h2> (Get Free Report)<p>Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.  </p><p>Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Gilead Sciences</li><li>Rewiring AI: NextEra Energy Sparks a Mega Merger</li><li>Flipping the Switch: Is Ford the Next Big Energy Stock?</li><li>Does Nano Nuclear Energy’s New Deal Amp the Outlook?</li><li>3 Dividend Stocks With Insiders Buying in 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2><p>Before you consider Gilead Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p><p>While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GILD

<p>Daiwa Securities Group has lowered its target price for Gilead Sciences (NASDAQ:GILD) from $161.00 to $150.00 while maintaining an 'outperform' rating. This new target suggests a potential upside of 14.66%. Other analysts have varied opinions, with Barclays setting a $155.00 target and Wells Fargo raising theirs to $165.00. Gilead's stock is currently trading at $130.82, with a market cap of $162.42 billion and a P/E ratio of 17.85.</p>

Market Beat

Gilead Sciences

SPDR S&P Biotech

iShares US Pharma

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VG Health

VanEck Biotech ETF

Daiwa Securities Group Inc.

Barclays

Wells Fargo

Mizuho Financial

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Mizuho Financial Group, Inc.

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price